Literature DB >> 18280586

Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin.

Thomas Nachreiner1, Florian Kampmeier, Theo Thepen, Rainer Fischer, Stefan Barth, Michael Stöcker.   

Abstract

We report the construction of a fusion protein comprising the extracellular domain of myelin oligodendrocyte glycoprotein (MOG) and a truncated version of Pseudomonas aeruginosa exotoxin A (ETA'). The chimeric immunotoxin targeted MOG-reactive B-lymphocytes by binding selectively to the appropriate receptors, leading to internalization and apoptosis of the target cells. The functionality of the immunotoxin was tested on a MOG-sensitive murine hybridoma cell line and ex vivo on freshly isolated splenocytes from transgenic IgH(MOG) mice. These data demonstrate, for the first time, the specific cytotoxicity of a MOG-containing recombinant immunotoxin expressed in bacteria towards MOG-reactive B-lymphocytes.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18280586     DOI： 10.1016/j.jneuroim.2008.01.001

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  9 in total

1.  Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.

Authors:  Judith Niesen; Christoph Stein; Hannes Brehm; Grit Hehmann-Titt; Rolf Fendel; Georg Melmer; Rainer Fischer; Stefan Barth
Journal:  J Cancer Res Clin Oncol       Date:  2015-04-22       Impact factor: 4.322

2.  Design of targeted B cell killing agents.

Authors:  Alexey V Stepanov; Alexey A Belogurov; Natalia A Ponomarenko; Oleg A Stremovskiy; Leonid V Kozlov; Anna M Bichucher; Sergey E Dmitriev; Ivan V Smirnov; Olga G Shamborant; Dmitry S Balabashin; Lidia P Sashchenko; Alexander G Tonevitsky; Alain Friboulet; Alexander G Gabibov; Sergey M Deyev
Journal:  PLoS One       Date:  2011-06-06       Impact factor: 3.240

3.  Generation of an artificial human B cell line test system using Transpo-mAbTM technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins.

Authors:  Diana Klose; Mira Woitok; Judith Niesen; Roger R Beerli; Ulf Grawunder; Rainer Fischer; Stefan Barth; Rolf Fendel; Thomas Nachreiner
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

4.  The riddle of lymphoma BCR-antigenes.

Authors:  Lorenz Thurner; Sylvia Hartmann; Klaus-Dieter Preuss; Moritz Bewarder
Journal:  Oncotarget       Date:  2018-11-09

5.  Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma.

Authors:  Moritz Bewarder; Maximilian Kiefer; Clara Moelle; Lisa Goerens; Stephan Stilgenbauer; Konstantinos Christofyllakis; Dominic Kaddu-Mulindwa; Natalie Fadle; Evi Regitz; Frank Neumann; Markus Hoth; Klaus-Dieter Preuss; Michael Pfreundschuh; Lorenz Thurner
Journal:  Front Oncol       Date:  2020-11-12       Impact factor: 6.244

Review 6.  Role of Specific B-Cell Receptor Antigens in Lymphomagenesis.

Authors:  Lorenz Thurner; Sylvia Hartmann; Frank Neumann; Markus Hoth; Stephan Stilgenbauer; Ralf Küppers; Klaus-Dieter Preuss; Moritz Bewarder
Journal:  Front Oncol       Date:  2020-12-09       Impact factor: 6.244

7.  B-cell receptors of EBV-negative Burkitt lymphoma bind modified isoforms of autoantigens.

Authors:  Theresa Bock; Moritz Bewarder; Onur Cetin; Natalie Fadle; Evi Regitz; Eva C Schwarz; Jana Held; Sophie Roth; Stefan Lohse; Thorsten Pfuhl; Rabea Wagener; Sigrun Smola; Sören L Becker; Rainer Maria Bohle; Lorenz Trümper; Reiner Siebert; Martin-Leo Hansmann; Michael Pfreundschuh; Hans G Drexler; Markus Hoth; Boris Kubuschok; Klaus Roemer; Klaus-Dieter Preuss; Sylvia Hartmann; Lorenz Thurner
Journal:  EJHaem       Date:  2022-06-16

8.  Novel fusion proteins for the antigen-specific staining and elimination of B cell receptor-positive cell populations demonstrated by a tetanus toxoid fragment C (TTC) model antigen.

Authors:  Diana Klose; Ute Saunders; Stefan Barth; Rainer Fischer; Annett Marita Jacobi; Thomas Nachreiner
Journal:  BMC Biotechnol       Date:  2016-02-17       Impact factor: 2.563

9.  Sequential Prodrug Strategy To Target and Eliminate ACPA-Selective Autoreactive B Cells.

Authors:  Lianne P W M Lelieveldt; Hendy Kristyanto; Ger J M Pruijn; Hans Ulrich Scherer; René E M Toes; Kimberly M Bonger
Journal:  Mol Pharm       Date:  2018-10-26       Impact factor: 4.939
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.